A Phase 1 interventional study of VNZ/TEZ/D-IVA and VNZ/TEZ/D-IVA in Cystic Fibrosis, sponsored by Vertex Pharmaceuticals Incorporated. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-26.
Sponsored by Vertex Pharmaceuticals Incorporated · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 125 studies in Cystic Fibrosis by Vertex Pharmaceuticals Incorporated — 3 open to participants now, 8 under way, 5 of them phase 3. Cystic Fibrosis · Vertex Pharmaceuticals Incorporated.
Among the 125 studies in Cystic Fibrosis by Vertex Pharmaceuticals Incorporated, this one is the 88th largest by enrollment of the 116 interventional ones that give a count, is one of 5 that started in 2024, is one of 28 in phase 1, and was the 116th registered.
1,621 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.
Browse Cystic Fibrosis studies →3 of the 125 studies in Cystic Fibrosis by Vertex Pharmaceuticals Incorporated are open now, in 10 countries. Recruiting first, the newest first:
Vertex Pharmaceuticals Incorporated · Sites in United States
Ages 18–55 · Healthy volunteers
Vertex Pharmaceuticals Incorporated · Sites in United States
Ages 18–55 · Healthy volunteers
Vertex Pharmaceuticals Incorporated · Sites in United States, Australia, Canada and 7 more countries
Ages 1+
By country, each count listing its studies:
Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 86 take children under 18; 41 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
125 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 31 · Phase 2 24 · Phase 3 62 · Phase 4 2
First in 2007; this study’s year is marked. 5 started in 2024.
This study's enrollment of 34 is close to the median of 36 across 1,053 interventional studies indexed under Cystic Fibrosis.
Median enrollment 73 across the 116 interventional studies, 79 across the 5 observational. Of the 112 that completed or were terminated, 80 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
Vertex Pharmaceuticals Incorporated is the lead sponsor of 249 studies on the registry; 17 are open to participants now.
Of its 107 completed or terminated interventional studies of FDA-regulated products, 54 (50%) have results posted.
4 of the studies in Cystic Fibrosis by Vertex Pharmaceuticals Incorporated that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05331183Phase 3Vertex Pharmaceuticals IncorporatedStudy to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508del | 2027-04-06 |
| NCT06460506Phase 3Vertex Pharmaceuticals IncorporatedEvaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis Participants 12 Months of Age and Older | 2027-09-30 |
| NCT07437105Vertex Pharmaceuticals IncorporatedDose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy Participants | 2027-06-26 |
| NCT07283770Vertex Pharmaceuticals IncorporatedEvaluation of VX-581 in Healthy Participants and in Participants With Cystic Fibrosis | 2027-07-12 |
Add all 4 to your calendar (.ics) → With an account.
Among the 125 studies in Cystic Fibrosis by Vertex Pharmaceuticals Incorporated, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the relative bioavailability, food effect, and dose proportionality of a granule formulation of VNZ/TEZ/D-IVA.
This clinical trial information was submitted voluntarily under the applicable law and, therefore, certain submission deadlines may not apply. (That is, clinical trial information for this applicable clinical trial was submitted under section 402(j)(4)(A) of the Public Health Service Act and 42 CFR 11.60 and is not subject to the deadlines established by sections 402(j)(2) and (3) of the Public Health Service Act or 42 CFR 11.24 and 11.44.).
Key Inclusion Criteria:
Key Exclusion Criteria:
Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive VNZ/TEZ/D-IVA reference fixed dose combination (FDC) tablet in dosing period 1, then VNZ/TEZ/D-IVA test FDC granules dose level 1 in dosing period 2, and finally VNZ/TEZ/D-IVA test FDC granules dose level 2 in dosing period 3. A washout period of 14 days will be maintained between 3 dosing periods.
Drug: VNZ/TEZ/D-IVA
Participants will receive VNZ/TEZ/D-IVA test FDC granules dose level 1 in dosing period 1, then VNZ/TEZ/D-IVA test FDC granules dose level 2 in dosing period 2, and finally VNZ/TEZ/D-IVA reference FDC tablet in dosing period 3. A washout period of 14 days will be maintained between 3 dosing periods.
Drug: VNZ/TEZ/D-IVA
Participants will receive VNZ/TEZ/D-IVA test FDC granules dose level 2 in dosing period 1, then VNZ/TEZ/D-IVA reference FDC tablet in dosing period 2, and finally VNZ/TEZ/D-IVA test FDC granules dose level 1 in dosing period 3. A washout period of 14 days will be maintained between 3 dosing periods.
Drug: VNZ/TEZ/D-IVA
Participants will receive VNZ/TEZ/D-IVA test FDC granules under fasted condition in dosing period 1, then VNZ/TEZ/D-IVA test FDC granules under fed state in dosing period 2. A washout period of 18 days will be maintained between 2 dosing periods.
Drug: VNZ/TEZ/D-IVA
Participants will receive VNZ/TEZ/D-IVA test FDC granules under fed state in dosing period 1, then VNZ/TEZ/D-IVA test FDC granules under fasted condition in dosing period 2. A washout period of 18 days will be maintained between 2 dosing periods.
Drug: VNZ/TEZ/D-IVA
FDC tablet for oral administration.
Also known as: VX-121/VX-661/CTP-656, VX-121/VX-661/VX-561, Vanzacaftor/tezacaftor/deutivacaftor
FDC granules for oral administration.
Also known as: VX-121/VX-661/CTP-656, VX-121/VX-661/VX-561, Vanzacaftor/tezacaftor/deutivacaftor
Part A: Maximum Observed Plasma Concentration (Cmax) of VNZ, TEZ, and D-IVA
Time frame: Pre-dose up to 288 hours Post-dose
Part B: Maximum Observed Plasma Concentration (Cmax) of VNZ, TEZ, and D-IVA
Time frame: Pre-dose up to 384 hours Post-dose
Part A: Area Under the Concentration Versus Time Curve (AUC) of VNZ, TEZ, and D-IVA
Time frame: Pre-dose up to 288 hours Post-dose
Part B: Area Under the Concentration Versus Time Curve (AUC) of VNZ, TEZ, and D-IVA
Time frame: Pre-dose up to 384 hours Post-dose
Part A: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time frame: Day 1 up to Day 42
Part B: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time frame: Day 1 up to Day 36
Plan to share: No — Details on Vertex data sharing criteria and process for requesting access can be found at: https://www.vrtx.com/independent-research/clinical-trial-data-sharing
No publications or documents are linked to this record.
Ran from Mar 2024 to primary completion in May 2024, 2 months.
Of 39 industry-sponsored phase 1 interventional studies under Cystic Fibrosis, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 16. This study's 2 months is below that.
Counting every sponsor, half of 62 studies reached it within 10 months; a quarter within 5 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Vertex Pharmaceuticals Incorporated →